MedPath
FDA Approval

TAVABOROLE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Cipla USA Inc.
DUNS: 078719707
Effective Date
January 9, 2024
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Tavaborole(43.5 mg in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Cipla USA Inc.

078719707

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Encube Ethicals Private Limited

Cipla USA Inc.

Cipla USA Inc.

725076298

AZICO BIOPHORE INDIA PRIVATE LIMITED

Cipla USA Inc.

Cipla USA Inc.

860186984

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

TAVABOROLE

Product Details

NDC Product Code
69097-686
Application Number
ANDA212224
Marketing Category
ANDA (C73584)
Route of Administration
TOPICAL
Effective Date
January 9, 2024
Code: K124A4EUQ3Class: ACTIBQuantity: 43.5 mg in 1 mL
ALCOHOLInactive
Code: 3K9958V90MClass: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGFClass: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3Class: IACT
© Copyright 2025. All Rights Reserved by MedPath